Clin Exp Vaccine Res.  2013 Jul;2(2):92-96. 10.7774/cevr.2013.2.2.92.

Herpes zoster vaccine in Korea

• Choi WS

• KMID: 2167718
• DOI: http://doi.org/10.7774/cevr.2013.2.2.92

Abstract

Herpes zoster and post-herpetic neuralgia deteriorate the quality of life because of severe pain and complications, and cause considerable social and economic burden of disease. In 2012, herpes zoster vaccine was released in Korea. The efficacy of herpes zoster vaccine is known to be 51.3-66.5% among the aged over 60 and 69.8-72.4% among adults between 50 and 59. It is also known that preventive efficacy is maintained for at least 5 years. Although there can be local reactions such as redness, pain and swelling at the site of injection and systemic reaction such as headache and eruption after herpes zoster vaccination, most of the adverse reactions are minor and disappear within days by themselves. As it is a live vaccine, persons with severe immune-suppression and pregnant women should not be vaccinated with the vaccine. Currently, Korean Society of Infectious Diseases recommended for the aged over 60 to be vaccinated with herpes zoster vaccine by subcutaneous route. In this article, clinical aspects and burden of disease of herpes zoster, efficacy and effects of herpes zoster vaccine, and herpes zoster vaccine recommendation by Korean Society of Infectious Diseases are discussed.

Keyword

Herpes zoster; Neuralgia; Vaccines; Republic of Korea; Review

MeSH Terms

Adult
Aged
Communicable Diseases
Female
Headache
Herpes Zoster
Herpes Zoster Vaccine
Humans
Korea
Neuralgia
Pregnant Women
Quality of Life
Republic of Korea
Vaccination
Vaccines
Herpes Zoster Vaccine
Vaccines

Reference

1. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004; 39:342–348.

2. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005; 352:2271–2284.

3. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007; 356:1338–1343.

4. Korean Society of Infectious Diseases. Vaccination for adult. 2nd ed. Seoul: MIP;2012.

5. Weaver BA. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc. 2007; 107:3 Suppl 1. S2–S7.

6. Katz J, Melzack R. Measurement of pain. Surg Clin North Am. 1999; 79:231–252.

7. Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008; 57:1–30.

8. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995; 155:1605–1609.

9. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005; 352:2266–2267.

10. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002; 347:340–346.

11. Choi WS, Noh JY, Huh JY, et al. Disease burden of herpes zoster in Korea. J Clin Virol. 2010; 47:325–329.

12. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis. 2009; 48:1364–1371.

13. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007; 82:1341–1349.

14. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008; 197:825–835.

15. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012; 55:1320–1328.

16. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012; 54:922–928.

17. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010; 28:4204–4209.

18. Tseng HF, Chi M, Smith N, Marcy SM, Sy LS, Jacobsen SJ. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012; 206:190–196.

19. MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥ 60 years old. Hum Vaccin. 2010; 6:894–902.

20. Tseng HF, Smith N, Sy LS, Jacobsen SJ. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011; 29:3628–3632.